Prostate Cancer Market to Reach $13.6 Billion Revenue Growth Till 2021

USA, February 24, 2016 (Newswire.com) - ​​Several drugs are expected to be approved during the forecast period 2014-2021: ProstAtak, ODM201, ARN-509, and Tookad. However, their sales are expected to be limited by high costs and a lack of comparative trials. But again, few years or a decade down the lane, the sales are expected to rise with various factors (given completely in the report)

With the anticipated approval of nine late-stage pipeline products within the forecast period, including the cancer vaccines Prostvac, DCVAC and ProstAtak, the Prostate Cancer Therapeutic Market will be boosted with positive results.

Global revenues for the PC market are forecast to rise at a moderate CAGR of 9.5% from $7.6bn in 2014 to $13.6 Billion to 2021.

Complete research on Prostate Cancer Market to 2021 available at http://www.marketintelreports.com/report/gbihc373mr/prostate-cancer-market-to-2021--increasing-disease-prevalence-to-be-a-key-driver-of-market-growth

Market Trends:

Prostate cancer is slow growing, many patients can leave their disease untreated for extended periods of time with frequent monitoring (watchful waiting or active surveillance), with many patients dying from other causes before treatment is indicated. Surgery and/or radiotherapy is often curative when treatment is indicated for localized disease, with androgen deprivation being the standard of first-line care. However, most patients ultimately develop resistant disease, for whom treatment options have historically been limited, with treatment with docetaxel being standard. The recent approval of Zytiga and Xtandi for docetaxel refractory disease in 2011 and 2012 have improved survival of resistant patients, but there is a clear clinical need to diversify the treatment options for this patient cohort.

Zytiga and Xtandi are both blockbuster drugs, with global sales in 2014 of $2.2 billion and $2.1 billion, respectively. While the strong sales growth of these products is beginning to plateau, it will continue to increase over the next few years, say market research experts.

Check research sample here http://www.marketintelreports.com/pdfdownload.php?id=gbihc373mr

Market Driving Factors:

Prostate Cancer is a disease with a slow growth process and asymptomatic at its earliest stages. This has been either causing early or late deaths in most number of cases. In order to change this scenario has taken birth, the prostate cancer treatment market. With the use of digital rectal examination, the PSA test, and the incidental discovery of tumors following resection of the prostate, the majority of Prostate Cancer cases are diagnosed at an early stage, approximately 60% (earlier than a conventional method for sure). This hope has been driving the overall Prostate cancer market.

The core reasons for the boosting of this industry are the rising number of aging population and the growth in prevalence of Prostate Cancer cases. Due to these major reasons, the global Prostate cancer market is expected to show healthy business opportunities in the observation period of 2014-2021.

Geographically, the Prostate cancer market analysis was done around the world with the eight major markets which will project high revenue generations being the US, Canada, France, Germany, Italy, Spain, the UK and Japan.

Key Vendors:

This report on Prostrate Cancer Market includes all the details of the top key players competing in the industry. The industry is studied in depth based on various factors and aspects.

Order a copy of Prostate Cancer Market to 2021report @ http://www.marketintelreports.com/purchase.php?id=gbihc373mr

Contact us:
Sales Manager
Mayur S.
2711 Centerville Road, Suite 400,
Wilmington, Delaware, 19808
United States
www.marketintelreports.com

sales@marketintelreports.com
Telephone : 1-302-684-6088